Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from alpha-tubulin sequence
- PMID: 15018907
- DOI: 10.1016/j.bmc.2004.01.014
Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from alpha-tubulin sequence
Abstract
A cyclic hexapeptide hydroxamic acid inhibitor for HDAC6 has been designed and synthesized on the basis of the facts that alpha-tubulin is the substrate of HDAC6 and of the excellent inhibitory activity of cyclic tetrapeptide hydroxamic acids (CHAPs) for HDACs. Unexpectedly, cyclic hexapeptide hydroxamic acid showed very low HDAC inhibitory activity. To explain the low activity, we have carried out conformation analysis and compared it to the crystal structure of alpha-tubulin. The conformation around the acetylated lysine of the cyclic hexapeptide substrate or the aminosuberate hydroxamic acid [Asu(NHOH)] of cyclic hexapeptide inhibitor is different from that around alpha-tubulin's lysine-40. The difference in the conformation seems to cause some steric hindrance at the capping site resulting in poor binding capacity.
Similar articles
-
Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.Bioorg Med Chem. 2005 Jul 1;13(13):4332-42. doi: 10.1016/j.bmc.2005.04.002. Bioorg Med Chem. 2005. PMID: 15927839
-
Design and synthesis of a potent histone deacetylase inhibitor.J Med Chem. 2007 May 3;50(9):2003-6. doi: 10.1021/jm061082q. Epub 2007 Apr 10. J Med Chem. 2007. PMID: 17419603
-
Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).Bioorg Med Chem. 2008 Feb 15;16(4):2011-33. doi: 10.1016/j.bmc.2007.10.092. Epub 2007 Nov 4. Bioorg Med Chem. 2008. PMID: 18054239
-
Histone deacetylase inhibitors that target tubulin.Cancer Lett. 2009 Aug 8;280(2):222-32. doi: 10.1016/j.canlet.2009.01.040. Epub 2009 Mar 5. Cancer Lett. 2009. PMID: 19268440 Review.
-
Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors.Curr Opin Drug Discov Devel. 2004 Nov;7(6):848-68. Curr Opin Drug Discov Devel. 2004. PMID: 15595445 Review.
Cited by
-
The ZIKV NS5 Protein Aberrantly Alters the Tubulin Cytoskeleton, Induces the Accumulation of Autophagic p62 and Affects IFN Production: HDAC6 Has Emerged as an Anti-NS5/ZIKV Factor.Cells. 2024 Mar 29;13(7):598. doi: 10.3390/cells13070598. Cells. 2024. PMID: 38607037 Free PMC article.
-
Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking study.Iran J Pharm Res. 2014 Fall;13(4):1165-72. Iran J Pharm Res. 2014. PMID: 25587304 Free PMC article.
-
Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.Bioorg Med Chem. 2014 Apr 1;22(7):2188-93. doi: 10.1016/j.bmc.2014.02.018. Epub 2014 Feb 22. Bioorg Med Chem. 2014. PMID: 24613456 Free PMC article.
-
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity.Mol Biol Cell. 2006 Aug;17(8):3435-45. doi: 10.1091/mbc.e06-01-0008. Epub 2006 May 31. Mol Biol Cell. 2006. PMID: 16738306 Free PMC article.
-
Influence of Hsp90 and HDAC inhibition and tubulin acetylation on perinuclear protein aggregation in human retinal pigment epithelial cells.J Biomed Biotechnol. 2011;2011:798052. doi: 10.1155/2011/798052. Epub 2010 Oct 24. J Biomed Biotechnol. 2011. PMID: 20981255 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources